GlassScriptPhysician profile
Margaret Tolar
NPI 1730965443
$1,692.75
in general payments reported to CMS, 2019-2025
19 companies · $877 in 2025
The $877 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $33.21 · 2024: $782 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $270.96 | 2024-2025 | |
| Novo Nordisk INC | $224.88 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $218.48 | 2023-2025 | |
| Lilly USA, LLC | $197.95 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $99.05 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $96.99 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.72 | 2024-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $90.39 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $86.33 | 2025 | Korlym |
| Abbott Laboratories | $68.36 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $56.17 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.20 | 2024-2025 | Relistor, Xifaxan |
| Astellas Pharma US INC | $30.31 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $29.77 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $24.16 | 2025 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $22.17 | 2024 | Fluad, Flucelvax |
| Renalytix Ai, INC. | $20.15 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Bayer Healthcare Pharmaceuticals INC. | $15.84 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.87 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Tolar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.